Status:
UNKNOWN
A Analgesic Study of Adductor Canal &IPACK Block with Liposomal Bupivacaine in Knee Arthroplasty
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Liposomal Bupivacaine
Postoperative Recovery
Eligibility:
All Genders
18-79 years
Phase:
PHASE4
Brief Summary
To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty
Detailed Description
The pain after knee arthroplasty limits the patient's activities and postoperative recovery, and currently there are mainly three analgesic methods: intravenous analgesia, epidural analgesia and nerve...
Eligibility Criteria
Inclusion
- Age 18-79 years.
- Patients undergoing unilateral total knee arthroplasty or unicondylar joint replacement.
- Normal diet.
- ASA grade I\~Ⅲ;
- BMI 18-30kg /m2.
- No intraspinal anesthesia contraindications.
Exclusion
- Patients with severe neurological diseases.
- Hearing and speech impaired.
- Preoperative gastric emptying disorders, such as gastrointestinal obstruction, gastroesophageal reflux, or previous gastrointestinal surgery, etc.
- Patients with severe renal insufficiency or other severe metabolic diseases.
- Mental disorders, alcoholism or a history of drug abuse.
- The surgical time is greater than 3 hours.
- Puncture site infection, abnormal coagulation function, and local anesthetic allergy.
Key Trial Info
Start Date :
December 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06145165
Start Date
December 10 2023
End Date
December 31 2024
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006